会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明专利
    • Pharmaceutical composites of poorly water soluble drugs and polymers
    • NZ713487A
    • 2017-04-28
    • NZ71348711
    • 2011-12-22
    • APTALIS PHARMA LTD
    • GATTI PAOLOCOLOMBO ITALOGERVASONI DARIOPIRONTI VINCENZAALBORGHETTI LIAFABIANI FLAVIOBOLTRI LUIGI
    • A61K9/14A61K31/18A61K31/216A61K31/44
    • Disclosed herein is a process for the preparation of a composite comprising at least one poorly soluble drug of Class II according to Biopharmaceutics Classification System (BCS) having low solubility and high gastrointestinal permeability, at least one polymeric carrier selected from the group consisting of cross-linked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose, cross-linked cyclodextrins, cross-linked dextran, cross-linked starch, cross-linked methylcellulose and at least one not chemically cross-linked polymer, which is both soluble in water and organic solvent selected from the group consisting of hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethycellulose acetate succinate, cellulose acetate trimellitate, acrylic and methacrylic polymers and their copolymers, methacrylic acid-methylmethacrylate copolymer, polyaminoalkyl methacrylate-methacrylic esters copolymer, dimethylaminoethyl methacrylate-butylmethacrylate-methylmethacrylate copolymer, vinylpyrrolidone-vinyl acetate copolymer, methylvinylether-maleic acid copolymer, polyethyleneglycol- caprolactame- vinylpyrrolidone copolymer, comprising the following steps: (1) Dissolving at least one poorly water soluble drug in a process solvent or process solvent mixture, wherein the solvent may is selected from methanol, ethanol, higher alcohols, acetone, chlorinated solvents, formamide, dimethylformamide, fluorinated hydrocarbons or mixture thereof; (2) Dissolving at least one not cross-linked polymer, which is both water and organic solvent soluble, into the drug solution of step (1); (3) Swelling at least one polymeric carrier with the solution prepared in step (2), thus obtaining a swollen composite; (4) Removing the process solvent from the swollen composite of step (3), wherein step (4) is carried out for a period of time which is equal or shorter than about 410 minutes and at a temperature from 35 to 60°C and wherein the process solvent is able to swell the polymeric carrier or to be absorbed by the polymeric carrier and to dissolve the poorly soluble drug and the water and organic solvent soluble not chemically cross-linked polymer.